Just one in four self-funded health plans covered these treatments as of 2023, so most have to save for them themselves
Participants received once-weekly subcutaneous retatrutide at 4 mg, 9 mg, or 12 mg, or placebo, for 80 weeks
The post hoc analysis of the SUSTAIN 6 trial revealed that once-weekly semaglutide reduced the risk of major adverse cardiovascular events in all subjects, regardless of gender, age, or baseline cardiovascular risk
The pattern suggests compounded semaglutide filled a genuine access gap rather than serving as a permanent alternative for most patients
The GLP-1 Nutritional Support Bundle brings together targeted nutritional support designed to help maintain lean muscle, support digestion, and promote microbiome balance during periods of reduced calorie intake
Degraded semaglutide may not produce the same clean GLP-1 receptor activation, potentially causing irregular GI symptoms